A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Erlotinib (Primary) ; Sirolimus (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.
- 22 Sep 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov record
- 01 Jun 2014 The trial design and progress status presented at 50th Annual Meeting of the American Society of Clinical Oncology.